PYGM and coronary artery disorder: Significantly elevated levels of GDF15 (CAD:1600 ± 188 pg/mL; control: 1003 ± 94.1 pg/mL; p = 0.039) and CPN1 (CAD: 142.5 ± 4.7 pg/mL; control: 126.2 ± 6.2 pg/mL; p = 0.04) could be detected in coronary artery disease patients, but the plasma concentrations of PYGM (CAD: 7740 ± 4.45 ng/mL; control: 1213 ± 0.76 ng/mL; p > 0.05) and clusterin (CAD: 972.4 ± 246.8 pg/mL; control: 942.4 ± 306 pg/mL; p > 0.05) did not differ compared to the control individuals.